Assistant

Ask questions, navigate pages, or type / for commands

Ask
Navigate
Command

NurExone Biologic Inc.NRX.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Israel · nurexone.com

NurExone Biologic Inc. is a biopharmaceutical company developing exosome-based therapies for spinal cord injuries and central nervous system indications. Its flagship ExoPTEN therapy has received FDA Orphan Drug Designation for acute spinal cord injury treatment, with preclinical studies demonstrating structural repair and full motor function recovery. The company is headquartered in Haifa, Israel, and is listed on the TSX Venture Exchange, Frankfurt Stock Exchange, and OTCQB.

Key ratios

ROA
-121.2%TTM
2025 -121.2%2024 -135.8%2023 -92.1%
ROE
-282.5%TTM
2025 -282.5%2024 -517.2%2023 -318.5%

Recent news

NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update 2026-09-18 · GlobeNewswireNurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update 2026-09-16 · GlobeNewswireNurExone and NanoPass Technologies to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications 2026-09-14 · GlobeNewswireNurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference 2026-08-28 · GlobeNewswireNurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy 2026-08-21 · GlobeNewswireNurExone Announces Closing of C$1,066,078 Private Placement 2026-08-20 · GlobeNewswireNurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model 2026-08-14 · GlobeNewswireNurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership 2026-08-12 · GlobeNewswireNurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness 2026-07-30 · GlobeNewswireCorporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors 2026-07-28 · GlobeNewswire
Track NRX.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer

An unhandled error has occurred. Reload 🗙